One, because in the trials so far, SM6 has been effective on it's own producing stable disease in 2 of the patients.
Two - all of the other patients produced partial response and SM6 seemed to make cancer cells sensitized to other treatments that had failed in the past.
Three - SM6 has an extremely low toxicity profile. It has hardly any side effects and the one reported is very mild. This means it can be paired up with other drugs without worrying about killing the patient.
Carfilzomib, on the other hand, is toxic as hell and has all sorts of nasty side effects. So they want to team with PAB to increase the effectiveness of their treatment without adding to the side effects
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.1¢ |
Change
-0.001(33.3%) |
Mkt cap ! $2.365M | |||
| Open | High | Low | Value | Volume |
| 0.1¢ | 0.1¢ | 0.1¢ | $199 | 198.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 74578882 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 32268741 | 22 |
View Market Depth
| Last trade - 15.36pm 04/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |